Federal regulators in the United States have given the green light to a new, more potent formulation of the popular obesity medication, Wegovy. This enhanced-dose version promises to assist individuals in achieving greater weight loss and, crucially, maintaining those results over the long term.
The U.S. Food and Drug Administration (FDA) has now approved a 7.2-milligram dose of semaglutide, the active ingredient in Wegovy, developed by Danish pharmaceutical giant Novo Nordisk. Up until this recent approval, the highest sanctioned dosage of this weekly injectable treatment was 2.4 milligrams. The expedited review process, facilitated by the FDA’s ultra-fast drug approval program, saw the request for review granted approval within a swift 54-day timeframe.
This higher-dose iteration, to be known as Wegovy HD, is slated for availability in pharmacies across the United States starting in April. The company indicated that pricing details will be disclosed at that time. European drug regulators had previously given their endorsement for this stronger Wegovy formulation in February.
Enhanced Efficacy in Clinical Trials
The clinical trials supporting the approval of Wegovy HD have demonstrated a significant improvement in weight loss outcomes. Participants receiving the higher 7.2-milligram dose experienced an average weight loss of approximately 19% of their total body weight, which translates to roughly 47 pounds. This stands in contrast to the approximately 16% body weight reduction, or 39 pounds, observed in individuals using the previously highest dose of 2.4 milligrams. These results were tracked over a period of nearly 17 months.
The development of this higher dose was a strategic response to observations that while the 2.4-milligram injection is effective for many, “some individuals do not reach their therapeutic goals” at this level. These findings were detailed in research published last year in the esteemed medical journal, Lancet Diabetes & Endocrinology.
A New Oral Option and Expert Perspectives
Adding to the evolving landscape of obesity treatment, the FDA also gave its approval in December for an oral formulation of Wegovy. This pill contains 25 milligrams of semaglutide, a concentration determined to be necessary for effective absorption through the digestive system.
Dr. Jody Dushay, an endocrinologist and recognised expert in obesity management at Harvard Medical School, has expressed her enthusiasm for the approval of the higher-dose injectable Wegovy. She noted that this new dosage “may be especially helpful for people” who are already tolerating the lower-dose version but have experienced “suboptimal weight loss.” Furthermore, Dr. Dushay suggested that it could also benefit individuals who have not achieved a substantial response to the highest available dose of Zepbound, a competing obesity drug from Eli Lilly.
Understanding Potential Side Effects
While the enhanced efficacy is a significant development, it’s important to acknowledge the associated side effects. The clinical study indicated that more than 70% of participants taking the higher 7.2-milligram dose of Wegovy reported side effects such as nausea, vomiting, and constipation. This compares to over 60% of those on the lower 2.4-milligram dose and approximately 43% of individuals in the placebo group.
A specific condition involving unpleasant skin sensations, described as burning, stabbing, or an electrical shock-like feeling, was also noted. This occurred in about 23% of those on the higher Wegovy dose, compared to 6% on the lower dose and less than 1% in the placebo group.
Regarding more serious adverse events, the study reported them in nearly 7% of participants receiving the 7.2-milligram dose of Wegovy. This was in contrast to about 11% of those on the 2.4-milligram dose and approximately 5% of individuals who received a placebo.
Dr. Dushay also pointed out that the increase in the maximum Wegovy dose from 2.4 milligrams to 7.2 milligrams represents “quite a big jump,” particularly in the absence of an intermediate dosage option. She emphasised the need to observe “if in the real world, versus in a clinical study, side effects are any worse.” This highlights the ongoing importance of real-world data collection and monitoring as the drug becomes more widely accessible.
